CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Hye Ryeon Kim, Su Jin Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Han-Sin Jeong, Man Ki Chung, Myung-Ju Ahn
Cancer Research and Treatment. 2022;54(3):719-727.   Published online 2021 November 1    DOI: https://doi.org/10.4143/crt.2021.1019

Excel Download

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Cancer Research and Treatment. 2022;54(3):719-727   Crossref logo
Link1 Link2 Link3

A Prospective Multicenter Phase II Study of Cisplatin and Weekly Docetaxel as First-Line Treatment of Recurrent or Metastatic NAsopharyngeal Cancer (KCSG HN07-01)
Annals of Oncology. 2012;23:xi156   Crossref logo
Link1 Link2

2300 A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine
European Journal of Cancer. 2015;51:S432   Crossref logo
Link1 Link2

1031 POSTER Weekly chemotherapy with cisplatin and docetaxel for recurrent metastatic head and neck cancer: a phase II study
European Journal of Cancer Supplements. 2005;3(2):297   Crossref logo
Link1 Link2

Phase II Study of Weekly Docetaxel and Cisplatin in Patients With Advanced Recurrent and Metastatic Head and Neck Cancer
The Laryngoscope. 2006;116(4):613-618   Crossref logo
Link1 Link2

88P Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Annals of Oncology. 2022;33:S1468-S1469   Crossref logo
Link1 Link2

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
Cancer Research and Treatment. 2017;49(3):706-716   Crossref logo
Link1 Link2 Link3

147PD A PHASE II STUDY OF WEEKLY PACLITAXEL PLUS GEMCITABINE AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OR RECURRENT SMALL CELL LUNG CANCER (SCLC)
Lung Cancer. 2009;64:S62   Crossref logo
Link1 Link2

A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
Cancer Chemotherapy and Pharmacology. 2009;66(1):31-36   Crossref logo
Link1 Link2 Link3

Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
Gynecologic Oncology. 2021;162:S89-S90   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.